What Will Happen If We Do Nothing To Control Trachoma: Health Expectancies for Blinding Trachoma in Southern Sudan

Jeremiah M. Ngondi1,2*, Fiona E. Matthews3, Mark H. Reacher1,4, Jonathan King2, Carol Brayne1, Hebe Gouda1, Paul M. Emerson2

1 Department of Public Health and Primary Care, Institute of Public Health, University of Cambridge, Cambridge, United Kingdom, 2 The Carter Center, Atlanta, Georgia, United States of America, 3 MRC Biostatistics Unit, Institute of Public Health, Cambridge, United Kingdom, 4 Health Protection Agency, East of England Regional Epidemiology Unit, Institute of Public Health, Cambridge, United Kingdom

Abstract

Background: Uncontrolled trachoma is a leading cause of blindness. Current global trachoma burden summary measures are presented as disability adjusted life years but have limitations due to inconsistent methods and inadequate population-based data on trachomatous low vision and blindness. We aimed to describe more completely the burden of blinding trachoma in Southern Sudan using health expectancies.

Methodology/Principal Findings: Age and gender specific trachomatous trichiasis (TT) prevalence was estimated from 11 districts in Southern Sudan. The distribution of visual acuity (VA) in persons with TT was recorded in one district. Sudan life tables, TT prevalence, and VA were used to calculate Trichiasis Free Life Expectancy (TFFLE) and Trichiasis Life Expectancy (TTLE) using the Sullivan method. TTLE was broken down by VA to derive TTLE with normal vision, TTLE with low vision, and TTLE with blindness. Total life expectancy at birth in 2001 was 54.2 years for males and 58.1 for females. From our Sullivan models, trichiasis life expectancy at the age of 5 years was estimated to be 7.0 (95% confidence interval [CI] = 6.2–7.8) years (12% [95% CI = 11–14] of remaining life) for males and 10.9 (95% CI = 9.9–11.9) years (18% [95% CI = 16–20] of remaining life) for females. Trichiasis life expectancy with low vision or blindness was 5.1 (95% CI = 3.9–6.4) years (9% [95% CI = 7–11] of remaining life) for males and 7.6 (95% CI = 6.0–9.1) years (12% [95% CI = 10–15] of remaining life) for males and females, respectively. Women were predicted to live longer and spend a greater proportion of their lives with disabling trichiasis, low vision, and blindness compared to men.

Conclusions: The study shows the future burden associated with doing nothing to control trachoma in Southern Sudan, that is, a substantial proportion of remaining life expectancy spent with trichiasis and low vision or blindness for both men and women, with a disproportionate burden falling on women.

Introduction

Trachoma is one of the oldest infectious diseases known to mankind and is the leading infectious cause of blindness, estimated to be responsible for 2.9% of blindness worldwide [1]. Recurrent infection with ocular Chlamydia trachomatis results in chronic inflammation, scarring, trichiasis, corneal opacification, and blindness [2–4]. Blindness due to trachoma is preventable through the World Health Organization (WHO) SAFE strategy which comprises: Surgery, eyelid surgery to correct in-turned eyelashes which stops pain and minimizes risk of corneal damage; Antibiotic treatment for active trachoma using single-dose oral azithromycin or topical tetracycline; Facial cleanliness, promotion of clean faces especially in children through sustained behaviour change; and Environmental improvements to increase access to water and sanitation [5].

Summary measures of population health, including disability adjusted life years (DALYs) [6] and handicap adjusted life years (HALYs) [7], have been used to estimate the global burden attributable to trachoma. DALYs and HALYs are population health measures permitting morbidity and mortality to be simultaneously described within a single number and estimate the gap between a population’s health and some defined goal. The methodology and data sources describing trachoma DALYs and HALYs have differed such that direct comparisons are not possible. For instance, Evans and Ranson estimated global burden of trachoma for the year 1990 to be 80.0 million HALYs [7]; while for the same years the Global Burden of Disease (GBD 1990) project reported trachoma burden to be 1.0 million DALYs [8]. Additionally, studies describing the global burden of trachoma for the year 2000 yielded different estimates of 2.2 million DALYs [6].
and 3.6 million DALYs [9]. These previous estimates also have limitations arising from paucity of population-based data on trachomatous low vision and blindness [7,9,10].

We aimed to demonstrate the application of the health expectancies approach for trachomatous trichiasis health states (any trichiasis, trichiasis with normal vision, trichiasis with low vision, and trichiasis with blindness) as a summary measure of trachoma burden using population-based survey data from Southern Sudan. Health expectancy is a measure that combines information on both mortality and morbidity to derive lengths of time spent in different states of health. The methods presented can be applied to other trachoma endemic areas and presents estimates of the potential burden of blinding trachoma if control measures are not implemented.

Methods

Ethics Statement

The Institutional Review Board of Emory University approved the survey protocols and clearance to conduct surveys was obtained from the Sudan Peoples Liberation Movement Secretariat of Health (SPLM/Health). Verbal informed consent to participate was sought from the heads of the household, from each individual and the parents of children aged less than 10 years in accordance with the declaration of Helsinki. Consent for household interviews and eye examination was documented by interviewers and examiners on the data collection forms. Personal identifiers were removed from the data set before analyses were undertaken.

Cross-Sectional Surveys

Surveys for trachoma were conducted in eleven districts in Southern Sudan between 2001 and 2006 [11–13]. For each district, the sample size was calculated to allow for estimation of at least 50% prevalence of active trachoma signs in children aged 1–9 years within a precision of 10% given a 95% confidence limit and a design effect of 5. We also aimed to estimate at least 2.5% prevalence of trachoma trichiasis (TT) in persons aged 15 years and above within a precision of 1.5% at 95% confidence limit and a design effect of 2. The districts were selected on the basis of pragmatic program implementation criteria of: 1) anecdotal reports of blinding trachoma; 2) security and accessibility; and 3) feasibility of initiating trachoma control interventions after the survey.

A two-stage cluster random sampling with probability proportional to size was used to select the sample population in each district. A cluster was defined as the population within a single village. Using a line listing of all the villages in each survey district, villages were grouped into sub-districts. Villages that were inaccessible and/or insecure were excluded from the sampling frame. In the first stage, villages were randomly selected with probability proportional to the estimated population of the sub-district. In the second stage, households were selected from the villages selected in the previous stage using the random-walk method [14], except in Ayod district where the compact segment method [15] was used for sampling households. All residents of selected households were enumerated and those present were eligible for eye examination. It was not possible to return later to the households to pick up any absentees and households where residents were not available were skipped.

Trachoma Examination

Trainee examiners comprising of auxiliary nurses and community health workers were trained using the WHO simplified grading system [16] by a senior examiner experienced in trachoma grading (ophthalmologist or ophthalmic nurse). The minimum accepted inter-observer agreement was set at 80% and reliability assessed in two stages. In the first stage, trainee examiners identified trachoma grades using the WHO sets of trachoma slides [17,18]. Those examiners who achieved at least 80% agreement then proceeded to the second stage of field evaluation. During field evaluation a reliability study comprising 50 persons of varying age and gender were selected by the ophthalmic nurse to represent all trachoma grades. Each trainee examiner evaluated all 50 subjects independently and recorded their findings on a pre-printed form. Inter-observer agreement was then calculated for each trainee using the senior examiners’ observation as the ‘gold standard’. Only trainees achieving at least 80% inter-observer agreement after the field evaluation were included as trachoma graders.

All persons living within each selected household who gave verbal consent were examined using a torch and a ×2.5 magnifying binocular loupe in accordance to the simplified grading system. Alcohol-soaked cotton-swabs were used to clean the examiner’s fingers between examinations. All examined participants were assigned a dichotomous outcome for each trachoma sign based on the worst affected eye. TT was defined by the presence of at least one eye lash touching the eyeball or evidence of epilation of the eyelashes. Individuals with signs of active trachoma were offered treatment with 1% tetracycline eye ointment. Patients TT were referred to the health centre where free eyelid surgery was available.

Visual Acuity Testing

In one district (Mankien), visual acuity (VA) testing was conducted in all eligible participants [19]. Experienced Integrated eye care workers (IECW) were re-trained in VA testing, basic eye examination and trachoma grading and their reliability assessed. Only trainees achieving an inter-observer agreement of 80% and above were eligible to participate as examiners. Prior to the survey, the minimum age for visual acuity (VA) testing was predetermined to be 5 years. VA testing was conducted outdoors in adequate sunlight using the Snellen E chart at 6 meters. In persons with VA<6/60, VA was evaluated with the Snellen chart at 3 meters. Further VA assessment was done in persons with VA<3/60 by
Data were recorded on a customized form and the cause of visual impairment determined for all subjects with a presenting VA of $<6/18$ for each eye separately. The principal disorder responsible for low vision or blindness was determined for the participant by taking into account the main cause for each individual eye. Vision loss was attributed to trachoma in persons presenting with trichiasis and corneal opacity. In the instance where different causes of vision loss had been identified for each eye separately in a given individual, the principal disorder was chosen to be the one that was most readily curable or, if not curable, most easily preventable (i.e. cataract, trachoma, non-trachomatous CO, and other causes in that order). To define the vision status we adopted the WHO categories of visual impairment based on presenting visual acuity (Box 1).

**Box 1. Definitions of vision status based on presenting visual acuity: adopted from international statistical classification of diseases and related health problems (ICD-10; Block H53-H54) [34]**

- **Blindness**: presenting visual acuity of less than 3/60 in the better eye
- **Low vision**: presenting visual acuity of less than 6/18 but equal to or better than 3/60 in the better eye
- **Normal vision**: presenting visual acuity of better than or equal to 6/18 in the better eye
- **Visual impairment**: refers to presence of either low vision or blindness

data from other populations judged to be similar and is indexed on the number of survivors at age five years and the number of survivors at age 60 years [21].

**Definition of Health States**

The health states used to describe the burden due to trachoma were defined as follows: Total Life Expectancy, the total lifespan at birth (years); Trichiasis Free Life Expectancy (TTLE), the expectation of life without any trichiasis; and Trichiasis Life Expectancy (TTE), the expectation of life with any trichiasis. TTE was then broken down into three health states: 1) TTLE with normal vision, the expectation of life with any trichiasis and normal vision (presenting VA $\geq 6/18$ in better eye); 2) TTLE with low vision, the expectation of life with any trichiasis and low vision (presenting VA $<6/18$ but $\geq 3/60$ in better eye); and 3) TTLE with blindness, the expectation of life with any trichiasis and blindness (presenting VA $<3/60$ in the better eye).

**Statistical Analysis**

The data analysis framework is summarised in Figure 1. Microsoft Excel spreadsheets developed by the European Health Expectancy Monitoring Unit were adapted for the calculation of health expectancies [22]. Age and gender specific prevalence of trichiasis was estimated from cross-sectional surveys and modelled using logistic regression to smooth the prevalence estimates. The distribution of vision status was derived from Mankien survey whereby visual acuity was categorized into normal vision, low vision and blindness; and modelled by ordinal logistic regression to provide proportions for each category of VA by age and gender [19]. The prevalence of vision status in the sample population was then calculated by multiplying the age and gender specific proportions of vision status with the smoothed prevalence of trichiasis. Life tables were collapsed to represent 5-year age-groups from age zero (0) to 75 years and above. Trichiasis Free Life Expectancy (TTLE) and Trichiasis Life Expectancy (TTE) were then calculated using the Sullivan method [23]. The Sullivan method combines use of life tables and age specific prevalence of morbidity to partition life expectancy into years with and without morbidity. The Sullivan health expectancy reflects the current health of the population adjusted for mortality levels and independent of age structure. Health expectancy calculated by the Sullivan method is the number of remaining years, at a particular age, that an individual can expect...
to live in a specified health state. Trichiasis Life Expectancy was further broken down by vision status to derive TTLE with normal vision, TTLE with low vision and TTLE with blindness.

**Results**

The Study Population, Prevalence of Trichiasis, and Trichiasis Vision Status

Table 1 summarises the study population. A total of 23,139 (87.2% of those enumerated) people, in 11 districts, were examined for trachoma of whom males comprised 43%. The overall prevalence of trachomatous trichiasis (all ages) was 6.0% (95% confidence interval [CI] = 5.2–7.0) and varied by district ranging from 0.7% in Katigiri to 10.0% in Kimotong. Of 341 people with TT in Mankien district, 319 were included in modelling of the distribution of vision status (i.e. TT with normal vision, TT with low vision and TT with blindness). The distribution of proportions of vision status by age and gender in persons with trichiasis is shown in Table 2.

**Table 1.** The study population and distribution of vision status.

| District  | Survey Year | Sample Population | Trachomatous Trichiasis |
|-----------|-------------|-------------------|-------------------------|
|           |             |                   | People Enumerated | People Examined | Response Rate (%) | People Examined % Males | Number of Cases | Prevalence % (95% CI) |
| Paluer    | 2002        | 3,650             | 2,999               | 82.2            | 39.9              | 162                      | 5.4 (4.2–6.9) |
| Padak     | 2002        | 2,277             | 1,822               | 80.0            | 46.8              | 87                       | 4.8 (3.0–7.5) |
| Kongor    | 2004        | 2,475             | 1,927               | 77.9            | 45.3              | 52                       | 2.7 (1.6–4.7) |
| Boma      | 2003        | 2,576             | 2,391               | 92.8            | 45.5              | 174                      | 7.3 (3.6–14.1) |
| Kiechkuon | 2002        | 1,738             | 1,530               | 88.0            | 37.9              | 125                      | 8.2 (6.5–10.3) |
| Mankien   | 2005        | 3,976             | 3,567               | 89.7            | 44.5              | 341                      | 9.6 (7.0–13.0) |
| Katigiri  | 2001        | 1,743             | 1,642               | 94.2            | 43.5              | 12                       | 0.7 (0.2–2.3) |
| Tali      | 2001        | 1,530             | 1,433               | 93.7            | 42.6              | 32                       | 2.2 (1.3–3.4) |
| Narus     | 2004        | 2,049             | 1,681               | 82.0            | 35.1              | 51                       | 3.0 (2.1–4.3) |
| Kimotong  | 2004        | 1,735             | 1,586               | 91.4            | 40.1              | 159                      | 10.0 (5.1–18.8) |
| Ayod      | 2006        | 2,605             | 2,561               | 98.3            | 48.0              | 182                      | 7.1 (5.8–10.8) |
| Total     |             | 26,354            | 23,139              | 87.8            | 43.0              | 1,377                    | 6.0 (5.2–7.0) |

doi:10.1371/journal.pntd.0000396.t001

**Table 2.** Distribution of predicted proportions of vision status by age group and gender in persons with trichiasis in Mankien district (n = 319).

| Age Group (years) | Vision Status** (%) |        |        |        |        |        |
|-------------------|---------------------|--------|--------|--------|--------|--------|
|                   | Males               | Females|
|                   | Normal Vision | Low Vision | Blindness | Normal Vision | Low Vision | Blindness |
| 0–4*              | 100.0               | 0        | 0      | 100.0 | 0        | 0       |
| 5–9               | 94.6                | 5.0      | 0.4    | 96.3  | 3.3      | 0.3     |
| 10–14             | 90.1                | 9.2      | 0.7    | 93.1  | 6.2      | 0.7     |
| 15–19             | 83.9                | 14.8     | 1.3    | 88.4  | 10.4     | 1.2     |
| 20–24             | 76.1                | 21.8     | 2.1    | 82.2  | 15.8     | 2.0     |
| 25–29             | 67.2                | 29.7     | 3.2    | 74.7  | 22.3     | 3.0     |
| 30–34             | 57.6                | 37.7     | 4.7    | 66.0  | 29.4     | 4.5     |
| 35–39             | 48.2                | 45.1     | 6.7    | 56.9  | 36.6     | 6.5     |
| 40–44             | 39.4                | 51.3     | 9.3    | 47.9  | 43.0     | 9.1     |
| 45–49             | 31.7                | 55.7     | 12.6   | 39.4  | 48.2     | 12.4    |
| 50–54             | 25.2                | 58.2     | 16.5   | 32.0  | 51.6     | 16.4    |
| 55–59             | 19.9                | 58.9     | 21.2   | 25.6  | 53.3     | 21.1    |
| 60–64             | 15.6                | 57.9     | 26.5   | 20.3  | 53.1     | 26.6    |
| 65–69             | 12.2                | 55.4     | 32.4   | 16.0  | 51.4     | 32.5    |
| 70–74             | 9.6                 | 51.8     | 38.6   | 12.6  | 48.4     | 38.9    |
| 75+               | 7.5                 | 47.4     | 45.0   | 10.0  | 44.6     | 45.5    |

*Children aged 0–4 years assumed to have normal vision.
**Vision status: Normal vision = presenting visual acuity of $\geq$6/18 in the better eye; Low vision = presenting visual acuity of <6/18 to $\leq$3/60 in the better eye; Blindness = presenting visual acuity of <3/60 in the better eye.

doi:10.1371/journal.pntd.0000396.t002
### Table 3. Age and gender specific prevalence of trichiasis and trichiasis vision status.

| Age Group (years) | Males | | | Females | | |
|-------------------|-------|----------------|----------------|----------------|----------------|----------------|
|                   | Number of People Surveyed | People with TT | TT Prevalence (Estimated) | TT Prevalence (Smoothed)* | Prevalence of Vision Status** | Number of People Surveyed | People with TT | TT Prevalence (Estimated) | TT Prevalence (Smoothed)* | Prevalence of Vision Status** |
|                   |       |           |                           |                           | Normal Vision | Low Vision | Blindness |       |           |                           |                           | Normal Vision | Low Vision | Blindness |
| 0–4               | 2,654 | 2         | 0.1%                      | 1.0%                      | 1.0%          | 0.0%      | 0.0%      | 2,504 | 7         | 0.3%                      | 1.5%                      | 1.3%          | 0.0%      | 0.0%      |
| 5–9               | 2,204 | 34        | 1.5%                      | 1.3%                      | 1.3%          | 0.1%      | 0.0%      | 2,316 | 45        | 1.9%                      | 2.0%                      | 1.7%          | 0.1%      | 0.0%      |
| 10–14             | 1,200 | 32        | 2.7%                      | 1.8%                      | 1.6%          | 0.2%      | 0.0%      | 1,198 | 47        | 3.9%                      | 2.7%                      | 2.3%          | 0.2%      | 0.0%      |
| 15–19             | 653   | 24        | 3.7%                      | 2.5%                      | 2.1%          | 0.4%      | 0.0%      | 1,026 | 41        | 4.0%                      | 3.6%                      | 2.9%          | 0.3%      | 0.0%      |
| 20–24             | 449   | 29        | 6.5%                      | 3.3%                      | 2.5%          | 0.7%      | 0.1%      | 1,110 | 43        | 3.9%                      | 4.9%                      | 3.7%          | 0.7%      | 0.1%      |
| 25–29             | 515   | 24        | 4.7%                      | 4.5%                      | 3.0%          | 1.3%      | 0.1%      | 1,229 | 77        | 6.3%                      | 6.5%                      | 4.5%          | 1.4%      | 0.2%      |
| 30–34             | 448   | 25        | 5.6%                      | 6.0%                      | 3.5%          | 2.3%      | 0.3%      | 1,006 | 78        | 7.8%                      | 8.6%                      | 5.4%          | 2.4%      | 0.4%      |
| 35–39             | 469   | 50        | 10.7%                     | 8.0%                      | 3.8%          | 3.6%      | 0.3%      | 806   | 89        | 11.0%                     | 11.4%                     | 6.2%          | 4.0%      | 0.7%      |
| 40–44             | 345   | 45        | 13.0%                     | 10.5%                     | 4.2%          | 5.4%      | 1.0%      | 573   | 86        | 15.0%                     | 14.9%                     | 6.9%          | 6.2%      | 1.3%      |
| 45–49             | 305   | 39        | 12.8%                     | 13.8%                     | 4.4%          | 7.7%      | 1.7%      | 481   | 115       | 23.9%                     | 19.2%                     | 7.4%          | 9.0%      | 2.3%      |
| 50–54             | 330   | 48        | 14.5%                     | 17.9%                     | 4.5%          | 10.4%     | 3.0%      | 426   | 131       | 30.8%                     | 24.5%                     | 7.6%          | 12.3%     | 3.9%      |
| 55–59             | 128   | 23        | 18.0%                     | 22.9%                     | 4.6%          | 13.5%     | 4.9%      | 145   | 45        | 31.0%                     | 30.6%                     | 7.7%          | 16.0%     | 6.4%      |
| 60–64             | 139   | 39        | 28.1%                     | 28.8%                     | 4.5%          | 16.6%     | 7.6%      | 220   | 85        | 38.6%                     | 37.5%                     | 7.5%          | 19.7%     | 9.9%      |
| 65–69             | 76    | 13        | 17.1%                     | 35.5%                     | 4.3%          | 19.6%     | 11.5%     | 70    | 21        | 30.0%                     | 44.9%                     | 7.2%          | 23.0%     | 14.6%     |
| 70–74             | 31    | 7         | 22.6%                     | 42.8%                     | 4.1%          | 22.1%     | 16.5%     | 49    | 16        | 32.7%                     | 52.6%                     | 6.7%          | 25.5%     | 20.5%     |
| 75+               | 14    | 7         | 50.0%                     | 50.4%                     | 3.8%          | 23.9%     | 22.7%     | 20    | 10        | 50.0%                     | 60.1%                     | 6.0%          | 26.9%     | 27.5%     |
| Total             | 9,960 | 441       |                           |                           | Normal Vision | Low Vision | Blindness | 13,179| 936       |                           |                           | Normal Vision | Low Vision | Blindness |

TT, trachomatous trichiasis.

*TT prevalence smoothed by fitting logistic regression curve to estimated TT prevalence.

**Vision status: Normal vision = presenting visual acuity of ≥6/18 in the better eye; Low vision = presenting visual acuity of <6/18 to ≥3/60 in the better eye; Blindness = presenting visual acuity of <3/60 in the better eye. Prevalence of vision status = smoothed TT prevalence × predicted probability of vision status derived from reference 14.

doi:10.1371/journal.pntd.0000396.t003
Table 3 summarises the age and gender specific prevalence of trichiasis and breakdown of prevalence of trichiasis vision status. The prevalence of TT increased with age and females were more likely to have TT compared to males, age adjusted Odds Ratio (OR) = 1.5 (95% CI = 1.3–1.7). Consistent with prevalence of trichiasis, prevalence of visual impairment (low vision and blindness) increased with age (Table 3).

Life Table Characteristics for Sudan

In the 2001 Sudan life table, women had a higher life expectancy at birth than men. The life expectancy at birth for Sudan was 50.1 years for females and 54.1 years for males. Life expectancy increased in age 5–9 years compared to life expectancy at birth (age 0–4 years) to 56.8 years in males and 60.7 for females; indicating the high under-five mortality rate.

Trichiasis Health Expectancies

Table 4, Figure 2 and Figure 3 show the life expectancy (LE) and proportions of total life expectancy, trichiasis free life expectancy (TTFLE), trichiasis life expectancy (TTE), and TTE with normal vision, TTE with low vision, and TTE with blindness. Females had a greater life expectancy at all ages (Figure 2) than males and a larger proportion of remaining life spent with trichiasis low vision or blindness (Figure 3). At age five, TTFLE was 49.5 years (88% of remaining life) and 49.8 years (82% of remaining life) in males and females, respectively. Males expected to live 7.0 (95% CI = 6.2–7.8) years (12% [95% CI = 11–14]) of remaining life with trichiasis at age five; of which 1.9 years (3% of remaining life), 3.5 years (6% of remaining life) and 1.6 years (3% of remaining life) would be lived with normal vision, low vision and blindness, respectively. At age five, females TTFLE was 10.9 (95% CI = 9.9–11.9) years (18% [95% CI = 16–20] of remaining life) of which trichiasis with normal vision, low vision and blindness comprised 3.3 years (6%), 4.9 years (8%) and 2.7 years (4%), respectively. For both genders, the proportion of life spent with trichiasis increased with age (Figure 3), by age 50 years, TTFLE was 30% (6.4 years) for males and 40% (9.5 years) for females. The proportion of remaining life with trachoma visual impairment (low vision or blindness) at age 50 was 26% (5.5 years) for males and 33% (7.7 years) for females.

Discussion

This study presents the application of health expectancies in describing the burden due to trachoma by dividing life expectancy into life spent without trichiasis and with trichiasis (trichiasis with normal vision, trichiasis with low vision and trichiasis with blindness). The methods can be applied to other trachoma endemic setting, and presents a technique of estimating the burden associated with uncontrolled trachoma. In Southern Sudan, life expectancy at birth for the year 2001 was 54.2 for men and 58.1 years for women. At age five years, men expected to live an eighth of remaining life with trichiasis and nearly a tenth of remaining life with visual impairment (low vision or blindness) due to trachoma. For women this rose to nearly a fifth of remaining life at age five with trichiasis and an eighth of remaining life with trachomatous visual impairment. Not only were women estimated to live longer, they were also expected to spend a greater amount of time with trichiasis, trichiasis with low vision, and trichiasis with blindness compared to men.

Health expectancy is a measure that combines information on both mortality and morbidity to derive lengths of time spent in different states of health. The Sullivan method for calculating health expectancies has advantages over previous summary measures of trachoma burden because it is presented in units of expected years of life with or without the disease condition. This is intuitively meaningful for policy makers and a non-technical audience, and compares favourably with other indicators such as mortality and incidence rates or disability adjusted life years (DALYs), which are not generally easily understood [24]. Other advantages of the method include simplicity and relative accuracy in addition to using data which are commonly available: prevalence data from surveys and life tables.

In common with other countries for which vital registration is not well established, the WHO life tables are the most authoritative for Southern Sudan. Until recently (April 2008), no population census has been undertaken for many years due to the civil war, and without any vital registration we acknowledge that the true picture for life expectancy in Southern Sudan is difficult to ascertain and may differ from the WHO estimates. Indeed, data collected during the war suggest a total life expectancy for both males and females of just 42 years [25]. However, the Modified Logit model life tables used by WHO were developed in order to address systematic deviations in mortality patterns observed as levels of child and adult mortality deviate from the standard, and this method has been used extensively by WHO to produce life tables for countries with poor vital registration [21].

Our study has a number of potential limitations. The random walk method, whilst acceptable for other purposes is not ideal where the outcome being assessed is one that is obvious to those involved in guiding the survey teams. Bias could have been introduced since the village guides may have been more likely to direct the survey teams to households where they knew there were persons with TT or visual impairment [26]. The Sullivan health expectancies are not appropriate for modelling dynamic changes associated with disease control interventions since it takes a long time for the age specific prevalence of a disability to reach the equilibrium values corresponding to the changes in age specific incidence rates [27]. In addition, cross-sectional data incorporate past recovery, incidence and death rates in the prevalence at particular ages; hence the effects of these rates on health expectancy are more difficult to disentangle [28]. Two other methods are used for calculating health expectancies: multiple-decrement life tables [29] and increment-decrement or multi-state life tables [30]. These methods employ longitudinal data and provide more robust basis for predicting service needs and may be useful in estimating the effects of trachoma control interventions, for instance, eyelid surgery for TT. However, unlike the Sullivan method, these later methods are less used due to lack of appropriate longitudinal data.

Data on distribution of vision status among persons with TT was only available for one district and these were applied to the population prevalence of TT calculated from a large sample from 11 districts, rather than modelling data for each district separately. However, a potential limitation with our VA models is that the effects of co-morbidity of other conditions leading to visual impairment such as refractive error were not controlled for in our model for distribution of VA [19]. Overall, there will be some people for whom this approach is likely to have resulted in an overestimate of trichiasis life expectancy. For others, this approach could have underestimated trichiasis life expectancy, since trachoma may have been causing a proportion of their vision loss, even if not the main cause of vision loss. The effects of co-morbidity thus operate in both directions and the overall bias in estimated potential gain in health expectancy is likely to be very small [31].

Consistent with other studies, our study showed longer life expectancy and trichiasis free life expectancy in females compared
| Age Group (years) | Males | | | | | | Females | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | Life Expectancy (LE) | Trichiasis Free Life Expectancy (TTFLE) | Trichiasis Life Expectancy (TTLE) | TTLE with Normal Vision | TTLE with Low Vision | TTLE with Blindness | Life Expectancy (LE) | Trichiasis Free Life Expectancy (TTFLE) | Trichiasis Life Expectancy (TTLE) | TTLE with Normal Vision | TTLE with Low Vision | TTLE with Blindness |
| | Years (%) | Years (%) | Years (%) | Years (%) | Years (%) | Years (%) | Years (%) | Years (%) | Years (%) | Years (%) | Years (%) | Years (%) |
| 0-4 | 54.2 | 48.0 (89) | 6.2 (11) | 1.7 (3) | 3.1 (6) | 1.4 (3) | 58.1 | 48.4 (83) | 9.7 (17) | 3.0 (5) | 4.3 (7) | 2.4 (4) |
| 5-9 | 56.8 | 49.8 (88) | 7.0 (12) | 1.9 (3) | 3.5 (6) | 1.6 (3) | 60.7 | 49.8 (82) | 10.9 (18) | 3.3 (6) | 4.9 (8) | 2.7 (4) |
| 10-14 | 52.4 | 45.4 (87) | 7.0 (13) | 1.8 (3) | 3.5 (7) | 1.7 (3) | 56.4 | 45.4 (81) | 10.9 (19) | 3.3 (6) | 4.9 (9) | 2.7 (5) |
| 15-19 | 47.8 | 40.8 (85) | 7.0 (15) | 1.7 (4) | 3.6 (7) | 1.7 (4) | 51.8 | 40.9 (79) | 10.9 (21) | 3.2 (6) | 5.0 (10) | 2.7 (5) |
| 20-24 | 43.3 | 36.3 (84) | 6.9 (16) | 1.7 (4) | 3.6 (8) | 1.7 (4) | 47.3 | 36.5 (77) | 10.8 (23) | 3.1 (6) | 5.0 (11) | 2.7 (6) |
| 25-29 | 39.3 | 32.3 (82) | 6.9 (18) | 1.6 (4) | 3.6 (9) | 1.7 (4) | 43.2 | 32.4 (75) | 10.8 (25) | 2.9 (7) | 5.1 (12) | 2.8 (6) |
| 30-34 | 35.5 | 28.5 (80) | 6.9 (20) | 1.5 (4) | 3.7 (10) | 1.8 (5) | 39.3 | 28.6 (73) | 10.7 (27) | 2.7 (7) | 5.1 (13) | 2.9 (7) |
| 35-39 | 31.8 | 24.9 (78) | 6.9 (22) | 1.4 (4) | 3.7 (12) | 1.8 (6) | 35.4 | 24.8 (70) | 10.6 (30) | 2.5 (7) | 5.2 (15) | 2.9 (8) |
| 40-44 | 28.2 | 21.4 (76) | 6.8 (24) | 1.2 (4) | 3.7 (13) | 1.9 (7) | 31.5 | 21.1 (67) | 10.4 (33) | 2.3 (7) | 5.1 (16) | 3.0 (9) |
| 45-49 | 24.6 | 17.9 (73) | 6.7 (27) | 1.1 (4) | 3.6 (15) | 1.9 (8) | 27.6 | 17.6 (64) | 10.0 (36) | 2.0 (7) | 5.0 (18) | 3.0 (11) |
| 50-54 | 21.0 | 14.6 (70) | 6.4 (30) | 0.9 (4) | 3.5 (17) | 2.0 (9) | 23.7 | 14.2 (60) | 9.5 (40) | 1.7 (7) | 4.7 (20) | 3.0 (13) |
| 55-59 | 17.7 | 11.6 (60) | 6.0 (34) | 0.8 (4) | 3.2 (18) | 2.0 (11) | 20.0 | 11.2 (56) | 8.8 (44) | 1.4 (7) | 4.4 (22) | 3.0 (15) |
| 60-64 | 14.6 | 9.0 (62) | 5.6 (38) | 0.6 (4) | 2.9 (20) | 2.0 (14) | 16.5 | 8.5 (52) | 8.0 (48) | 1.1 (7) | 3.9 (24) | 2.9 (18) |
| 65-69 | 11.8 | 6.8 (57) | 5.0 (43) | 0.5 (4) | 2.6 (22) | 2.0 (17) | 13.2 | 6.3 (47) | 7.0 (53) | 0.9 (7) | 3.3 (25) | 2.8 (21) |
| 70-74 | 9.3 | 4.9 (53) | 4.3 (47) | 0.4 (4) | 2.1 (23) | 1.8 (20) | 10.4 | 4.5 (43) | 5.9 (57) | 0.7 (6) | 2.7 (26) | 2.5 (24) |
| 75+ | 7.2 | 3.6 (50) | 3.6 (50) | 0.3 (4) | 1.7 (24) | 1.6 (23) | 8.1 | 3.2 (40) | 4.9 (60) | 0.5 (6) | 2.2 (27) | 2.2 (27) |

(%) = proportion of remaining life.
doi:10.1371/journal.pntd.0000396.t004
Figure 2. Trichiasis free life expectancy (TTFLE), Trichiasis life expectancy (TTLE) with normal vision, TTLE with low vision and TTLE with blindness by gender. Normal vision = presenting visual acuity of $\geq 6/18$ in the better eye; Low vision = presenting visual acuity of $<6/18$ to $\geq 3/60$ in the better eye; Blindness = presenting visual acuity of $<3/60$ in the better eye.

doi:10.1371/journal.pntd.0000396.g002

Figure 3. Proportion of life expectancy: without trichiasis; with trichiasis and with normal vision; with trichiasis and low vision; and with trichiasis and blindness by gender. Normal vision = presenting visual acuity of $\geq 6/18$ in the better eye; Low vision = presenting visual acuity of $<6/18$ to $\geq 3/60$ in the better eye; Blindness = presenting visual acuity of $<3/60$ in the better eye.

doi:10.1371/journal.pntd.0000396.g003
to males. In addition, females experienced greater proportions of years lived with trichiasis. Generally, the greater proportion of years lived with disability in females has been suggested to be as a result of longer overall survival or longer survival after the development of disability or disease [32]. Survey data from most trachoma-endemic countries have consistently found the prevalence of scarring, trichiasis, and trachoma related blindness to be higher in females compared to males [33]. Therefore, the female excess in low vision or blindness associated with trichiasis is consistent with both greater survival and greater risk of trachomatous blindness among females.

Conclusion

We have presented the burden of trachomatous vision loss by age and gender using health expectancies. These data are of value in advocacy for trachoma control in engagement with politicians and donors. Unless action is taken by further delivery of trachoma control interventions, then populations in Southern Sudan can expect to spend a substantial proportion of their life with low vision or blindness due to trachoma.

Acknowledgments

We thank the following collaborating non-governmental organizations who were instrumental in facilitating the surveys: The Carter Center; Sudan Peoples Liberation Movement Secretariat of Health; Sudan Relief and Rehabilitation Commission; County Health Departments; Association of Christian Relief Associations Serving Sudan; Adventist Development and Relief Association; Christian Mission Aid; MEDAIR; Southern Sudan Operational Mercy; Sudan Medical Care; and ZOA Refugee Care.

Author Contributions

Conceived and designed the experiments: JMN FEM MHR JK CB HG PML. Performed the experiments: JMN JK. Analyzed the data: JMN FEM. Wrote the paper: JMN FEM MHR JK CB HG PML.

References

1. Resnikoff S, Pascolini D, Mariotti SP, Pokharel GP (2008) Global magnitude of visual impairment caused by uncorrected refractive errors in 2004. Bull World Health Organ 86: 63–70.
2. Ward M, Bailey R, Lesley A, Kajbaf M, Robertson J, et al. (1990) Persisting inapparent chlamydial infection in a trachoma endemic community in The Gambia. Scand J Infect Dis Suppl 69: 137–140.
3. Murray C, Lopez A, Turner V, Mathers C (1997) Incidence estimates of late stages of trachoma among women in a hyperendemic area of central Tanzania. Trop Med Int Health 2: 1030–1038.
4. Bowman RJ, Faal H, Myatt M, Azebola R, Foster A, et al. (2002) Longitudinal study of trachomatous trichiasis in the Gambia. Br J Ophthalmol 86: 339–343.
5. World Health Organization (1996) Future Approaches to Trachoma Control. Geneva: WHO, 1997, WHO document WHO/PBL/96.36.
6. Shibusaya K, Mariotti S, Mathers C (2006) Global burden of trachoma in the year 2000: summary of methods and data sources. Geneva: World Health Organization, Available: http://www.who.int/healthinfo/statistics/bod_trachoma.pdf (Accessed 2 March 2007).
7. Evans TG, Ranson MK (1995) The global burden of trachomatous visual impairment: I. Assessing burden. Int Ophthalmol 19: 271–280.
8. Murray C, Lopez AD (1996) The Global Burden of Disease. Boston, MA: Harvard University Press.
9. Frick KD, Basilion EV, Hanson CL, Colchero MA (2005) Estimating the burden and economic impact of trachomatous visual loss. Ophthalmic Epidemiol 10: 121–132.
10. Ranson MK, Evans TG (1995) The global burden of trachomatous visual impairment: I. Assessing prevalence. Int Ophthalmol 19: 261–270.
11. Ngondi J, Onsango A, Adama L, Metende I, Baba S, et al. (2005) The epidemiology of trachoma in Eastern Equatoria and Upper Nile States, southern Sudan. Bull World Health Organ 83: 904–912.
12. Ngondi J, Olse-Semple F, Onsango A, Metende I, Baba S, et al. (2006) Blinding Trachoma in Postconflict Southern Sudan. PLoS Negl Trop Dis 2: e299. doi:10.1371/journal.pntd.0000478.
13. King JG, Ngondi J, Gartan G, Loguidia B, Becknell S, et al. (2008) The burden of trachoma in Ayod county of Southern Sudan. PLoS Negl Trop Dis 2: e289. doi:10.1371/journal.pntd.0000299.
14. World Health Organization (1991) Training for mid-level managers: The EPI coverage survey. Geneva: WHO, WHO document WHO/EPI/MLM/91.10.
15. Turner AG, Magnani RJ, Shuaib M (1996) A not quite as quick but much cleaner alternative to the Expanded Programme on Immunization (EPI) Cluster Survey design. Int J Epidemiol 25: 198–203.
16. Thylefors B, Dawson CR, Jones BR, West SK, Taylor HR (1987) A simple system for the assessment of trachoma and its complications. Bull World Health Organ 63: 477–483.
17. World Health Organization (1993) Primary health care level management of trachoma. Geneva: WHO, WHO document WHO/PBL/93.33.
18. Solomon AW, Zondervan M, Kuper H, Buchanan J, Mabey, D, et al. (2006) Trachoma control: a guide for programme managers. Geneva: World Health Organization.
19. Ngondi J, Reacher M, Matthews F, Ole-Semple F, Onsango A, et al. (2007) The epidemiology of low vision and blindness associated with trachiasis in southern Sudan. BMC Ophthalmol 7: 12.
20. World Health Organization Statistical Information System (WHOSIS) (2006) Life tables for WHO member states. Available: http://www.who.int/whosis/en/ (Accessed 5 October 2007).
21. Murray C, Lopez A, Guillot M, Salomon, J, Ahmad O (2000) Modified logit life table system: principles, empirical validation and application. GPE discussion paper No. 39. Evidence and Information for Policy (EIP), World Health Organization. Available: http://www.who.int/healthinfo/paper39.pdf (Accessed 5 October 2007).
22. Jagger C, Cox B, Le Roy S, EHEMU (2006) Health Expectancy Calculation by the Sullivan Method. Third Edition. EHEMU Technical Report September 2006. Available: http://www.ehemu.eu/pdf/CalculationGuide.pdf (accessed on 18th February 2007).
23. Sullivan DF (1971) A single index of mortality and morbidity. HMSHA Health Rep 86: 347–354.
24. Mathers CD, Sadana R, Salomon JA, Murray CJ, Lopez AD (2001) Healthy life expectancy in 191 countries, 1990. Lancet 357: 1683–1691.
25. New Sudan Center for Statistics and Evaluation/UNICEF (2004) Towards a baseline: best estimates of social indicators for southern Sudan. Available: http://ssccse.org/blog/files/Towards-Baseline.pdf (Accessed 20 June 2008).
26. Ngondi J, Ole-Semple F, Onsango A, Metende I, Baba S, et al. (2006) Prevalence and causes of blindness and low vision in southern Sudan. PLoS Med 3: e477. doi:10.1371/journal.pmed.0030477.
27. Mathers CD, Robine JM (1997) How good is Sullivan’s method for monitoring changes in population health expectancies? J Epidemiol Community Health 51: 86–86.
28. Jagger C, Raymond N, Morgan K (1998) Planning for the future: the effect of changing mortality, incidence and recovery on life expectancy with visual disability. J Aging Health 10: 154–170.
29. Katz S, Branch LG, Brann MH, Papisadero JA, Beck JC, et al. (1983) Active life expectancy. N Engl J Med 309: 1218–1224.
30. Rogers A, Rogers RG, Branch LG (1989) A multivariate analysis of active life expectancy. Public Health Rep 104: 222–226.
31. Mathers CD (2003) Cause-deleted Health Expectancies. In: Robine JM, Jagger C, Mathers CD, Grimmins E, Summen R, eds. Determining Health Expectancies. Chichester, England: John Wiley & Sons, Ltd. pp 149–174.
32. Robine JM, Ronieux I, Canibus E (1999) Health expectancy indicators. Bull World Health Organ 77: 181–185.
33. Courrigh P, West SK (2004) Contribution of sex-linked biology and gender roles to disparities with trachoma. Emerg Infect Dis 10: 202–2016.
34. World Health Organization (2004) Diseases of the eye and adnexa. In: International statistical classification of diseases and related health problems: ICD-10, tenth revision - volume 1. Geneva: World Health Organization. pp 426–428.